Canopy Growth (CGC) EBT Margin (2019 - 2026)
Canopy Growth (CGC) posted EBT Margin of 50.3% for Q4 2025, down 604.01% sequentially from 7.14% in Q3 2025, and up 8048.0% YoY from 0.62% in Q4 2024.
Canopy Growth (CGC) EBT Margin (2019 - 2026) Analysis & Trends
Canopy Growth has reported EBT Margin for 7 years, with the latest figure at 50.3% in Q4 2025.
- Quarterly EBT Margin rose 8048.0% year-over-year to 50.3% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 59.46% (up 10846.0% YoY) and the FY2026 annual result came in at 422.48%, down 127021.0% from the prior year.
- EBT Margin slipped to 50.3% in Q4 2025 per CGC's latest filing, from 7.14% in the prior quarter.
- Over five years, EBT Margin peaked at 288.42% in Q2 2021 and troughed at 1759.55% in Q2 2022.
- A 5-year average of 212.6% and a median of 153.65% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2021 and 2022: EBT Margin jumped 478671 bps in 2021, then slumped 204797 bps in 2022.
- Over 5 years, EBT Margin stood at 74.62% in 2021, then sank by 260 bps to 268.92% in 2022, then dropped by 4 bps to 280.52% in 2023, then surged by 53 bps to 130.77% in 2024, then soared by 62 bps to 50.3% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 50.3%, 7.14%, and 61.79% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Canopy Growth | 441.27 Mn | 194.25 Mn | 16.08 Mn | -14.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.65% |
| Dec 31, 2025 | -50.30% |
| Sep 30, 2025 | -7.14% |
| Jun 30, 2025 | -61.79% |
| Dec 31, 2024 | -130.77% |
| Sep 30, 2024 | -177.67% |
| Jun 30, 2024 | -153.65% |
| Mar 31, 2024 | -209.19% |
| Dec 31, 2023 | -280.52% |
| Sep 30, 2023 | -182.09% |
| Jun 30, 2023 | -11.21% |
| Mar 31, 2023 | -519.95% |
| Dec 31, 2022 | -268.92% |
| Sep 30, 2022 | -214.06% |
| Jun 30, 2022 | -1,759.55% |
| Mar 31, 2022 | 151.59% |
| Dec 31, 2021 | -74.62% |
| Sep 30, 2021 | -14.87% |
| Jun 30, 2021 | 288.42% |
| Mar 31, 2021 | -363.11% |